oportuzumab monatox oportuzumab monatox oportuzumab monatox is an experimental anti-cancer medication. chemically, oportuzumab is a single chain variable fragment of a monoclonal antibody which binds to epithelial cell adhesion molecule (epcam, the tumor-associated calcium signal transducer 1). oportuzumab is fused with pseudomonas aeruginosa exotoxin a (which is reflected by the monatox in the medication's name). oportuzumab monatoxmonoclonal antibodytypesingle-chain variable fragmentsourcehumanizedtargetepcamclinical dataother namesoportuzumab monatox-qqrsatc codel01fx16 (who) identifierscas number945228-48-8 ndrugbankdb05319 ychemspidernoneunii945cy7zmi2keggd11913chemical and physical dataformulac3072h4723n877o952s12molar mass69558.48 g·mol−1 ny (what is this?) (verify) the drug was developed by canadian-based viventia bio inc. the company was acquired by cambridge(ma)-based eleven biotherapeutics in 2016, which then changed its name to sesen bio. in 2019 sesen bio reported updated, preliminary primary and secondary endpoint data from the company's phase 3 vista trial further supporting the strong benefit-risk profile of vicineum for the potential treatment of patients with high-risk, bacillus calmette-guérin(bcg) unresponsive, non-muscle invasive bladder cancer (nmibc). the company applied for approval of vicineum by the united states food and drug administration and the european medicines agency.